CGC — Canopy Growth Corporation
Is CGC overbought or oversold? Here is the current MarketMoodz read.
Canopy Growth Corporation (CGC) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $0.55. The rating moved from Oversold to Strong Oversold on November 13, 2026.
- Public ratingStrong Oversold (as of November 17, 2026)
- Last close$0.55
- Last changeMoved from Oversold to Strong Oversold on November 13, 2026
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
See all oversold Healthcare stocks →
AI analysis
Canopy Growth Corporation (CGC) is operating with notable balance sheet stress and ongoing operating losses despite scale and well‑known consumer brands in Canada and select markets. Near‑term improvement depends on successful execution of cost reductions, reduction of cash burn, and access to non‑dilutive financing; U.S. federal legalization remains an uncertain upside catalyst. Given current liquidity needs, high share float and sector competitive dynamics, downside remains more likely in the short term absent clear evidence of sustained margin recovery or major regulatory progress.
Key factors
- Weak financial position: persistent operating losses and cash burn create a need for recurring financing or asset sales
- Large brand and scale in Canadian and selected international recreational/medical markets provide structural market share advantages versus smaller peers
- Limited near‑term catalyst from U.S. federal legalization uncertainty; domestic Canadian market growth is slow and competitive
- Management actions to cut costs and rationalize footprint should reduce runway pressure but take time to materially improve margins
- Sector sentiment remains mixed; broader risk‑on flows favor growth but cannabis equities have lagged and retail enthusiasm is uneven
- High share float and low per‑share price amplify volatility and increase dilution sensitivity when capital is raised
Risks
- Need for additional financing leading to meaningful dilution (convertible financings or equity raises)
- Prolonged weak consumer demand or pricing pressure in core markets due to oversupply and increased competition
- Regulatory setbacks or slower-than-expected policy progress in key markets (U.S. federal reform, export/import rules)
- Execution risk on cost‑cutting and asset rationalization; expenses could remain elevated if restructuring is ineffective
- Adverse macro conditions that reduce discretionary spending and retail cannabis sales
- Liquidity risk and potential for continued high share price volatility
See today's live rating, score and targets
Members see the live hourly rating for CGC — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.